Kiniksa Pharmaceuticals International Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 366

Employees

  • Stock Symbol
  • KNSA

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $93.89
  • (As of Friday Closing)

Kiniksa Pharmaceuticals International General Information

Description

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Contact Information

Website
www.kiniksa.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 100 Hayden Avenue
  • Lexington, MA 02421
  • United States
+1 (781)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 100 Hayden Avenue
  • Lexington, MA 02421
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kiniksa Pharmaceuticals International Stock Performance

As of 20-Nov-2026, Kiniksa Pharmaceuticals International’s stock price is $93.89. Its current market cap is $7.38B with 78.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$93.89 $93.48 $37.02 - $99.31 $7.38B 78.6M 659K $1.42

Kiniksa Pharmaceuticals International Financials Summary

As of 30-Sep-2026, Kiniksa Pharmaceuticals International has a trailing 12-month revenue of $946M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 5,304,341 2,784,191 1,214,962 1,045,615
Revenue 945,963 677,564 423,239 270,259
EBITDA 148,049 90,422 (34,457) (14,311)
Net Income 109,568 59,005 (43,193) 14,084
Total Assets 983,243 763,633 580,553 526,322
Total Debt 7,884 9,497 9,855 12,258
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kiniksa Pharmaceuticals International Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kiniksa Pharmaceuticals International‘s full profile, request access.

Request a free trial

Kiniksa Pharmaceuticals International Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquirin
Biotechnology
Lexington, MA
366 As of 2025

Stamford, CT
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kiniksa Pharmaceuticals International Competitors (75)

One of Kiniksa Pharmaceuticals International’s 75 competitors is SpringWorks Therapeutics, a Formerly VC-backed company based in Stamford, CT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
SpringWorks Therapeutics Formerly VC-backed Stamford, CT
Aura Biosciences Formerly VC-backed Boston, MA
Beam Therapeutics Formerly VC-backed Cambridge, MA
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Santhera Pharmaceuticals Holding Formerly VC-backed Pratteln, Switzerland
You’re viewing 5 of 75 competitors. Get the full list »

Kiniksa Pharmaceuticals International Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kiniksa Pharmaceuticals International Investments & Acquisitions (2)

Kiniksa Pharmaceuticals International’s most recent deal was a Merger/Acquisition with Primatope Therapeutics for . The deal was made on 01-Jan-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Primatope Therapeutics 01-Jan-2019 Merger/Acquisition Other Healthcare Services
Biogen (Biogen Assets in Cambridge, Massachusetts) 01-Sep-2016 Corporate Asset Purchase Buildings and Property
To view Kiniksa Pharmaceuticals International’s complete investments and acquisitions history, request access »

Kiniksa Pharmaceuticals International ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Kiniksa Pharmaceuticals International’s complete esg history, request access »

Kiniksa Pharmaceuticals International FAQs

  • When was Kiniksa Pharmaceuticals International founded?

    Kiniksa Pharmaceuticals International was founded in 2015.

  • Where is Kiniksa Pharmaceuticals International headquartered?

    Kiniksa Pharmaceuticals International is headquartered in Lexington, MA.

  • What is the size of Kiniksa Pharmaceuticals International?

    Kiniksa Pharmaceuticals International has 366 total employees.

  • What industry is Kiniksa Pharmaceuticals International in?

    Kiniksa Pharmaceuticals International’s primary industry is Biotechnology.

  • Is Kiniksa Pharmaceuticals International a private or public company?

    Kiniksa Pharmaceuticals International is a Public company.

  • What is Kiniksa Pharmaceuticals International’s stock symbol?

    The ticker symbol for Kiniksa Pharmaceuticals International is KNSA.

  • What is the current stock price of Kiniksa Pharmaceuticals International?

    As of 20-Nov-2026 the stock price of Kiniksa Pharmaceuticals International is $93.89.

  • What is the current market cap of Kiniksa Pharmaceuticals International?

    The current market capitalization of Kiniksa Pharmaceuticals International is $7.38B.

  • What is Kiniksa Pharmaceuticals International’s current revenue?

    The trailing twelve month revenue for Kiniksa Pharmaceuticals International is $946M.

  • Who are Kiniksa Pharmaceuticals International’s competitors?

    SpringWorks Therapeutics, Aura Biosciences, Beam Therapeutics, Sarepta Therapeutics, and Santhera Pharmaceuticals Holding are some of the 75 competitors of Kiniksa Pharmaceuticals International.

  • What is Kiniksa Pharmaceuticals International’s annual earnings per share (EPS)?

    Kiniksa Pharmaceuticals International’s EPS for 12 months was $1.42.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process